Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

30.39
+1.093.72%
Post-market: 30.390.00000.00%19:32 EST
Volume:1.99M
Turnover:58.73M
Market Cap:2.80B
PE:-29.94
High:30.44
Open:29.48
Low:27.47
Close:29.30
52wk High:42.13
52wk Low:12.91
Shares:92.24M
Float Shares:91.22M
Volume Ratio:1.06
T/O Rate:2.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0152
EPS(LYR):-4.0759
ROE:-57.80%
ROA:-6.55%
PB:24.41
PE(LYR):-7.46

Loading ...

Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (IART) and Travere Therapeutics (TVTX)

TIPRANKS
·
Feb 21

Wedbush Sticks to Its Buy Rating for Travere Therapeutics (TVTX)

TIPRANKS
·
Feb 20

Stock Track | Travere Therapeutics Plunges 5.09% After-Hours on Mixed Earnings and Insider Selling

Stock Track
·
Feb 20

Travere Q4 product sales surge on FILSPARI growth

Reuters
·
Feb 20

Travere Therapeutics Chief Legal Officer Elizabeth E. Reed Disposes of Common Shares

Reuters
·
Feb 20

Stock Track | Travere Therapeutics Soars 5.31% Intraday on Strong Q4 Earnings Results

Stock Track
·
Feb 20

BRIEF-Travere Therapeutics Q4 EPS USD 0.03

Reuters
·
Feb 20

Travere Therapeutics Q4 Product Sales USD 126.608 Million

THOMSON REUTERS
·
Feb 20

Travere Therapeutics Inc. to Report Fourth Quarter and Full Year Financial Results

Reuters
·
Feb 13

Travere Therapeutics Grants Inducement RSUs to Ten New Employees

Reuters
·
Feb 12

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Feb 12

Travere Therapeutics präsentiert sich auf dem Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 05

Travere Therapeutics (TVTX) Faces FILSPARI Delay and Legal Scrutiny Is Execution Risk Repricing Ahead?

Simply Wall St.
·
Jan 30

Travere Therapeutics CEO Eric M. Dube Reports Disposal of Common Shares

Reuters
·
Jan 28

H.C. Wainwright Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
Jan 28

Assessing Travere Therapeutics (TVTX) Valuation As FDA Extends FILSPARI Review For FSGS Approval

Simply Wall St.
·
Jan 26

Chief Legal Officer Elizabeth E. Reed Reports Disposal of Travere Therapeutics Inc. Common Shares

Reuters
·
Jan 22

Travere Therapeutics put volume heavy and directionally bearish

TIPRANKS
·
Jan 22

Travere Therapeutics Highlights Growth Strategy and Pipeline Advances in Rare Kidney and Metabolic Diseases Presentation

Reuters
·
Jan 17

Stock Track | Travere Therapeutics Plummets 5.43% Intraday as FDA Delays Review of Key Kidney Drug

Stock Track
·
Jan 14